Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NYSE:PKI

Revvity (PKI) Stock Price, News & Analysis

Revvity logo

About Revvity Stock (NYSE:PKI)

Key Stats

Today's Range
N/A
50-Day Range
$115.24
$137.11
52-Week Range
N/A
Volume
1.63 million shs
Average Volume
851,117 shs
Market Capitalization
$14.57 billion
P/E Ratio
15.01
Dividend Yield
0.24%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Revvity, Inc provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. It focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics.? The company was founded by Richard Scott Perkin and Charles W. Elmer on April 19, 1937, and is headquartered in Waltham, MA.

Revvity Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
72nd Percentile Overall Score

PKI MarketRank™: 

Revvity scored higher than 72% of companies evaluated by MarketBeat, and ranked 303rd out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Revvity.

  • Earnings Growth

    Earnings for Revvity are expected to grow by 17.71% in the coming year, from $4.97 to $5.85 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Revvity is 15.01, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 113.12.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Revvity is 15.01, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 87.42.

  • Price to Earnings Growth Ratio

    Revvity has a PEG Ratio of 0.50. PEG Ratios below 1 indicate that a company could be undervalued.

  • Short Interest

    There is no current short interest data available for PKI.
  • Dividend Yield

    Revvity has a dividend yield of 0.24%, which is in the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Revvity does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Revvity is 3.65%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, Revvity will have a dividend payout ratio of 4.79% next year. This indicates that Revvity will be able to sustain or increase its dividend.

  • Read more about Revvity's dividend.
  • Short Interest

    There is no current short interest data available for PKI.
  • Search Interest

    Only 1 people have searched for PKI on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Revvity insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.52% of the stock of Revvity is held by insiders.

  • Percentage Held by Institutions

    85.22% of the stock of Revvity is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Revvity's insider trading history.
Receive PKI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Revvity and its competitors with MarketBeat's FREE daily newsletter.

PKI Stock News Headlines

Revvity, Inc. (RVTY)
70%, 80%, 90% Win Rates? Grab Your Free Cheatsheets Today!
Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets.
Revvity Inc PKI
See More Headlines

PKI Stock Analysis - Frequently Asked Questions

Revvity, Inc. (NYSE:PKI) announced its quarterly earnings data on Thursday, May, 11th. The medical research company reported $1.01 EPS for the quarter, missing the consensus estimate of $1.07 by $0.06. The medical research company had revenue of $674.87 million for the quarter, compared to analyst estimates of $686.30 million. Revvity had a trailing twelve-month return on equity of 11.17% and a net margin of 28.94%.

Revvity's Board of Directors approved a stock buyback plan on Thursday, May 11th 2023, which permits the company to buy back $600,000,000 in shares, according to EventVestor. This means that the company could buy up to 4.1% of its shares through open market purchases. Shares repurchase plans are often a sign that the company's management believes its stock is undervalued.

Revvity subsidiaries include these companies: BioLegend, Immunodiagnostic Systems, Nexcelom Bioscience, SIRION Biotech, Oxford Immunotec, Horizon Discovery, Cisbio.com, and others.

Based on aggregate information from My MarketBeat watchlists, some other companies that Revvity investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Meta Platforms (META), Visa (V), Home Depot (HD) and JPMorgan Chase & Co. (JPM).

Company Calendar

Last Earnings
5/11/2023
Today
12/24/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
CUSIP
71404610
Employees
16,700
Year Founded
1937

Profitability

Net Income
$569.18 million
Pretax Margin
13.81%

Debt

Sales & Book Value

Annual Sales
$3.31 billion
Book Value
$58.49 per share

Miscellaneous

Free Float
125,755,000
Market Cap
$14.57 billion
Optionable
Optionable
Beta
1.10

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

This page (NYSE:PKI) was last updated on 12/25/2024 by MarketBeat.com Staff
From Our Partners